Wolverine Asset Management’s Ionis Pharmaceuticals IONS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.63M | Hold |
35,000
| – | – | 0.03% | 492 |
|
|
2025
Q4 | $2.77M | Hold |
35,000
| – | – | 0.02% | 503 |
|
|
2025
Q3 | $2.29M | Hold |
35,000
| – | – | 0.02% | 525 |
|
|
2025
Q2 | $1.38M | Hold |
35,000
| – | – | 0.01% | 620 |
|
|
2025
Q1 | $1.06M | Hold |
35,000
| – | – | 0.01% | 672 |
|
|
2024
Q4 | $1.22M | Buy |
+35,000
| New | +$1.31M | 0.01% | 642 |
|
|
2023
Q1 | – | Sell |
-100
| Closed | -$3.78K | – | 1984 |
|
|
2022
Q4 | $3.78K | Hold |
100
| – | – | ﹤0.01% | 1778 |
|
|
2022
Q3 | $4K | Buy |
+100
| New | +$4.21K | ﹤0.01% | 2176 |
|
|
2022
Q1 | – | Sell |
-3,000
| Closed | -$91K | – | 2258 |
|
|
2021
Q4 | $91K | Hold |
3,000
| – | – | ﹤0.01% | 1385 |
|
|
2021
Q3 | $100K | Hold |
3,000
| – | – | ﹤0.01% | 1295 |
|
|
2021
Q2 | $119K | Hold |
3,000
| – | – | ﹤0.01% | 1425 |
|
|
2021
Q1 | $134K | Sell |
3,000
-1,800
| -38% | -$100K | ﹤0.01% | 1368 |
|
|
2020
Q4 | $271K | Hold |
4,800
| – | – | ﹤0.01% | 1013 |
|
|
2020
Q3 | $227K | Buy |
4,800
+3,000
| +167% | +$167K | ﹤0.01% | 945 |
|
|
2020
Q2 | $106K | Hold |
1,800
| – | – | ﹤0.01% | 1088 |
|
|
2020
Q1 | $85K | Hold |
1,800
| – | – | ﹤0.01% | 1080 |
|
|
2019
Q4 | $108K | Buy |
+1,800
| New | +$107K | ﹤0.01% | 1061 |
|
|
2019
Q2 | – | Sell |
-6,800
| Closed | -$551K | – | 1510 |
|
|
2019
Q1 | $551K | Buy |
+6,800
| New | +$439K | 0.01% | 824 |
|
|
2018
Q2 | – | Sell |
-14,100
| Closed | -$621K | – | 1505 |
|
|
2018
Q1 | $621K | Sell |
14,100
-35,300
| -71% | -$1.79M | 0.01% | 930 |
|
|
2017
Q4 | $2.48M | Sell |
49,400
-18,800
| -28% | -$1.03M | 0.03% | 445 |
|
|
2017
Q3 | $3.46M | Sell |
68,200
-10,400
| -13% | -$545K | 0.04% | 330 |
|
|
2017
Q2 | $4M | Sell |
78,600
-47,400
| -38% | -$2.21M | 0.05% | 278 |
|
|
2017
Q1 | $5.07M | Buy |
126,000
+33,300
| +36% | +$1.5M | 0.08% | 222 |
|
|
2016
Q4 | $4.43M | Sell |
92,700
-19,100
| -17% | -$756K | 0.06% | 256 |
|
|
2016
Q3 | $4.1M | Buy |
111,800
+3,200
| +3% | +$100K | 0.06% | 280 |
|
|
2016
Q2 | $2.53M | Buy |
108,600
+108,330
| +40,122% | +$3.49M | 0.04% | 390 |
|
|
2016
Q1 | $124K | Sell |
270
-271
| -50% | -$11K | ﹤0.01% | 738 |
|
|
2015
Q4 | $49K | Buy |
541
+100
| +23% | +$5.4K | ﹤0.01% | 1148 |
|
|
2015
Q3 | $160K | Hold |
441
| – | – | ﹤0.01% | 969 |
|
|
2015
Q2 | $72K | Hold |
441
| – | – | ﹤0.01% | 1209 |
|
|
2015
Q1 | $95K | Sell |
441
-511
| -54% | -$34.7K | ﹤0.01% | 1089 |
|
|
2014
Q4 | $239K | Buy |
952
+900
| +1,731% | +$44.4K | ﹤0.01% | 874 |
|
|
2014
Q3 | $16K | Hold |
52
| – | – | ﹤0.01% | 1870 |
|
|
2014
Q2 | $28K | Hold |
52
| – | – | ﹤0.01% | 1598 |
|
|
2014
Q1 | $22K | Sell |
52
-1,104
| -96% | -$53.5K | ﹤0.01% | 1608 |
|
|
2013
Q4 | $24K | Sell |
1,156
-160
| -12% | -$5.7K | ﹤0.01% | 2013 |
|
|
2013
Q3 | $57K | Buy |
+1,316
| New | +$39.3K | ﹤0.01% | 1675 |
|
Other funds holding IONS
VPM
VCM
Wolverine Asset Management's IONS Position: Q1 2026 in Review
Wolverine Asset Management reduced its Ionis Pharmaceuticals (IONS) stake by 25% in Q1 2026, selling an estimated $608K and leaving 22,815 shares worth $1.71M. The position accounts for 0.02% of the portfolio, ranked #613.
Wolverine Asset Management first reported a position in IONS in Q4 2016 and has held it in 5 quarters since. The position peaked at $8.98M in Q4 2016. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.
- Wolverine Asset Management held 22,815 shares of Ionis Pharmaceuticals worth $1.71M as of Q1 2026.
- Wolverine Asset Management sold 7,700 Ionis Pharmaceuticals shares in Q1 2026, an estimated $608K.
- Ionis Pharmaceuticals made up 0.02% of Wolverine Asset Management's portfolio in Q1 2026, its #613 holding.
- Wolverine Asset Management first reported a position in Ionis Pharmaceuticals in Q4 2016 and has held it in 5 quarters since.
- Wolverine Asset Management's Ionis Pharmaceuticals position peaked at $8.98M in Q4 2016.
- 493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.
Based on Wolverine Asset Management's 13F filing for Q1 2026, filed 4 May 2026.